Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo

Main Article Content

Dirk Schadendorf
Reinhard Dummer
Axel Hauschild
Mario Santinami
Victoria Atkinson
Mario Mandala
Vanna Chiarion-Sileni
James Larkin
Marta Nyakas
Caroline Dutriaux
Andrew Haydon
Laurent Mortier
Caroline Robert
Jacob Schachter
Christine-Elke Ortmann
Egbert de Jong
Edward Gasal
Richard Kefford
John M Kirkwood
Georgina V Long

Keywords

melanoma, BRAF V600, dabrafenib, trametinib

Abstract

Abstract not available.

References

1. Hauschild A, et al. J Clin Oncol. 2018;36:3441-3449.

2. Long GV, et al. N Engl J Med. 2017;377:1813-1823.

3. Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.

4. Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.

5. Tafinlar (dabrafenib) [summary of product characteristics]. Camberley, UK: Novartis Pharmaceuticals UK Ltd; 2018.
https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Accessed April 18, 2019.

6. Mekinist (trametinib) [summary of product characteristics]. Camberley, UK: Novartis Pharmaceuticals UK Ltd; 2019.
https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Accessed April 18, 2019.

7. Dummer R, et al. ESMO 2018 [poster 1250P].